Bosnia and Herzegovina’s pharmaceutical sector has the capacity and highly skilled personnel to develop and manufacture new pharmaceutical products.
In the present worldwide context created by the Covid-19, new emerging growth prospects exist for the pharmaceutical, biotechnology, and healthcare sectors. Bosnia and Herzegovina has suitable preconditions for investments in these sectors, including the appropriate regulatory framework, sophisticated laboratories with international accreditation, existing pharmaceutical production that operates successfully on three continents, and, most importantly, scientists and highly professional, specialized staff who are constantly improving and harmonizing business with national and international pharmaceutical regulations and standards.
In 2018, the top 10 pharmaceutical companies in Bosnia and Herzegovina generated approximately EUR 566 million and a profit of EUR 27 million. The company from Sarajevo Canton, Bosnalijek, was best ranked with the highest realized profit of approximately EUR 6 million.